[HTML][HTML] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Final …
Background Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA
mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth …
mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth …
[HTML][HTML] Efficacy of PI3K inhibitors in advanced breast cancer
B Verret, J Cortes, T Bachelot, F Andre, M Arnedos - Annals of Oncology, 2019 - Elsevier
Abstract The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a
focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration …
focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration …
[HTML][HTML] Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy
Breast cancer is the most prevalent type of cancer among women. Several types of drugs,
targeting the specific proteins expressed on the breast cancer cell surface (such as receptor …
targeting the specific proteins expressed on the breast cancer cell surface (such as receptor …
PIK3CA Mutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in …
S Loibl, G Von Minckwitz, A Schneeweiss… - Journal of clinical …, 2014 - ascopubs.org
Purpose Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in
breast cancer, with mutations in PIK3CA being the most common. This study investigated the …
breast cancer, with mutations in PIK3CA being the most common. This study investigated the …
Alpelisib (ALP)+ fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial
F André, EM Ciruelos, G Rubovszky… - Annals of …, 2018 - annalsofoncology.org
Background: Hyperactivation of the phosphatidylinositol-3-kinase (PI3K) pathway can occur
due to PIK3CA mutations, present in∼ 40% of patients (pts) with hormone receptor-positive …
due to PIK3CA mutations, present in∼ 40% of patients (pts) with hormone receptor-positive …
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative …
HS Rugo, F Lerebours, E Ciruelos, P Drullinsky… - 2020 - ascopubs.org
1006 Background: PIK3CA mutations (mut) occur in~ 40% of pts with HR+, HER2–ABC and
are associated with poor prognosis and resistance to treatment (tx). ALP, a PI3Kα inhibitor …
are associated with poor prognosis and resistance to treatment (tx). ALP, a PI3Kα inhibitor …
PI3K inhibitors in breast cancer therapy
H Ellis, CX Ma - Current oncology reports, 2019 - Springer
Abstract Purpose of Review The phosphatidylinositol 3-kinase (PI3K) pathway is the most
common aberrantly activated pathway in breast cancer, making it an attractive therapeutic …
common aberrantly activated pathway in breast cancer, making it an attractive therapeutic …
Drugging the PI3K/AKT/mTOR pathway in ER+ breast cancer
The frequent activation of the PI3K/AKT/mTOR pathway and its crucial role in estrogen
receptor-positive (ER+) breast cancer tumorigenesis and drug resistance has made it a …
receptor-positive (ER+) breast cancer tumorigenesis and drug resistance has made it a …
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
S Jain, AN Shah, CA Santa-Maria, K Siziopikou… - Breast cancer research …, 2018 - Springer
Purpose Activation of the phosphoinositide 3-kinase (PI3K) pathway is an important
resistance mechanism to anti-HER2 therapies. This study aimed to assess the safety and …
resistance mechanism to anti-HER2 therapies. This study aimed to assess the safety and …
Abstract GS3-08: Alpelisib+ fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial
Background: Hyperactivation of the phosphatidylinositol-3-kinase (PI3K) pathway can occur
due to PIK3CA mutations, present in~ 40% of patients (pts) with hormone receptor-positive …
due to PIK3CA mutations, present in~ 40% of patients (pts) with hormone receptor-positive …